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ABSTRACT 
Objective: The aim of the present study was to assess the prevalence, risk rating and the severity of hazardous pDDIs (potential drug-drug 
interactions) in the prescribed pharmacotherapy in the hospital discharged heart failure (HF) patients, primarily with co-administered drugs with 
narrow therapeutic index (statins, anticoagulants, antithrombotic drugs).  
Methods: The prescriptions of chronic heart failure patients for one year (January-December 2014) were analyzed for pDDIs through Lexi-interact® 
software. DDIs belonging to the categories D (Consider therapy modification) and X (Avoid combination) and/or severity of drug interaction-major, 
were selected for the study.  
Results: After reviewing the medical records of 985 patients, 239 patients were selected based on the criteria mentioned above. The average 
number of prescription drugs at hospital discharge was 7.27 medications (±1.84 SD) per patient. The total number of pDDIs was 1483 or 
approximately 6.2 (±3.89 SD) pDDIs per patient. With respect to the risk rating, in categories D and X were detected 76 (5.12 %) and 2 (0.13 %) 
pDDI, respectively. The major pDDIs were 108 (7.28 %). 
Conclusion: HF patients are at high risk of pDDIs. Screening of prescriptions for pDDIs and monitoring of pharmacotherapy in terms of response 
and associated adverse drug events will contribute to patient safety.  
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Heart failure (HF) affects more than 20 million people worldwide, with 
a 6-10% prevalence of people over 65 y of age [1]. HF is the end stage 
of cardiac disease and is accompanied by several co-morbid conditions 
with the most common being hypertension, ischemic heart disease, 
hyperlipidemia, anemia, diabetes, arthritis, chronic kidney disease, 
chronic obstructive pulmonary disease (COPD), atrial fibrillation (AF), 
and Alzheimer’s disease/dementia [2]. Therefore, the therapeutic 
regimens for the treatment of HF are very complex, including many 
pharmacological groups, and thus leading to polypharmacy, with great 
potential of drug-drug interactions (DDIs) [3-5]. There is no consensus 
on the definition of "polypharmacy", but in order to facilitate and 
reduce the degree of confusion, we will apply the most commonly used 
definition in the scientific literature, namely, the use of five or more 
drugs simultaneously [6]. "Polypharmacy" often leads to an increased 
risk of drug-related adverse reactions [7]. The older population is 
most affected by polypharmacy and its consequences. Increasing the 
prevalence of age-related chronic illnesses is accompanied by 
increased drug intake, as in the case with patients with HF. 
In general, drug interactions can be considered at two levels: 
pharmacokinetic (PK) and pharmacodynamic (PD). PK interactions 
are those that occur in the processes of absorption, distribution, 
metabolism or drug excretion, as the latter two processes are seen 
as elimination processes. Most of these processes are carried out 
with the help of protein molecules-transporters (influx or efflux), 
plasma proteins, cytochrome enzymes etc., where through 
competitive interactions or modulation of their function, the most 
clinically relevant drug interactions occur [8, 9]. Due to the 
remarkable individual variability in these processes, interactions 
can be expected, but their rate cannot be predicted easily. Such 
interactions may result in a change in the concentration of the drug 
at the site of action with subsequent toxicity or reduced efficacy. PD 
drug interactions occur when two or more drugs have mechanisms 
of action that affect the same physiological process. Influencing the 
physiological response of these two drugs may be in the same 
direction and then is referred to as synergism, and may also be in 
the opposite direction, and then the designation is antagonism [10]. 
The main purpose of the present study was to assess the prevalence, 
risk rating and severity of hazardous pDDIs in the prescribed 
pharmacotherapy, primarily with co-administered drugs with 
narrow therapeutic index (statins, anticoagulants, antithrombotic 
drugs) of the discharged HF patients, to evaluate their clinical 
relevance, and to describe their possible mechanism of interaction.  
MATERIALS AND METHODS 
The medical records of 985 patients for a one-year period (January-
December 2014) at “St. Marina” University Hospital in Varna, Bulgaria 
were retrospectively analyzed for potential DDIs at hospital discharge 
using a computerized drug interaction program-Lexicomp®, Lexi-
interact (Wolters Kluwer, Hudson, OH) [11]. The main inclusion 
criteria in the study were: 1) the diagnosis of HF with 2-4 class of 
NYHA; 2) receiving standard treatment (e. g. ACE-inhibitors or AT1-
blockers and/or beta-blockers, and/or diuretics, etc.); 3) concomitant 
use of medications threatened by pDDIs, due to a narrow safety 
margin, such as statins, anticoagulants (acenocoumarol or NOACs) and 
antithrombotic drugs (clopidogrel, prasugrel or ticagrelor). The main 
measure criteria were the detection of pDDIs falling into risk rating 
categories D (Consider therapy modification) and X (Avoid 
combination), or based on the severity of the drug interaction-major.  
Statistical analysis 
The results were presented as mean±standard deviation (SD) and 
ordinal and nominal data were shown as number (n) and percentage 
(%). The statistical analysis has been done by using Excel 2016 and 
SigmaPlot 11.0 Software. p<0.05 was selected as the level of 
statistical significance. 
The Committee on Research Ethics at the Medical University 
"Paraskev Stoyanov" Varna/Bulgaria approved the following study 
(Protocol number 84/27.06.2019). The completely patient 
information was kept in privacy and was not available in public. 
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RESULTS 
After reviewing the medical records of 985 patients who have 
passed through the Cardiology Clinic at St. Marina University 
Hospital in Varna, Bulgaria, 239 patients were selected, based on the 
criteria mentioned above, and the risk of drug interactions was 
checked with the indicated software. The workflow of the study is 
presented in fig. 1. 
  
 
Fig. 1: Workflow of the study 
 
The demographic characteristics of the selected patients showed almost 
identical gender distribution, men vs women 1:1.3. According to age, the 
majority of patients were in the elderly group (>60)-199 (83.3 %). The 
average age was 70.34 (±10.31 SD). The range of prescribed drugs was 
between four and thirteen, with an average at hospital discharge-7.27 
medications (±1.84 SD) per patient. Regarding the stage of the disease, 
the majority of patients were in the third stage of HF (NYHA)-222 (92.9 
%). All of the patients were with hypertension, the other accompanying 
diseases included atrial fibrillation (41 %), diabetes mellitus (41 %), and 
anemia (40.6 %). Reduced kidney function (eGFR<60 ml/min/m2) was 
detected in 87 (36.1%), while kidney failure (eGFR<30 ml/min/m2)-in 
23 (9.5%) of the patients (table 1). 
 
Table 1: General patient characteristics selected for the study 
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Average age male 
Average age female 
2 (0.8%) 
38 (15.9 %) 
199 (83.3 %) 
70.34 (±10.31 SD) 
69.58 (±10.66 SD) 
70.93 (±10.04 SD) 















15 (6.28 %) 
222 (92.9 %) 
2 (0.8%) 
Main co-morbid condition  
Hypertension 
Atrial fibrillation  
Diabetes mellitus 
Anemia 
239 (100 %) 
99 (41 %) 
98 (41 %) 
97 (40.6 %) 





DDIs Detected by Lexicomp® 
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The total number of pDDIs was 1484 or approximately 6.2 (±3.89 SD) 
pDDIs per one person. According to the risk rating of the software, 
DDIs were classified as category A (No known interactions), B (No 
action needed), C (Monitor therapy), D (Consider therapy 
modification) and X (Avoid combination). The most common drug 
interactions with respect to the risk rating were in group C-587, 
requiring careful monitoring of patients. In the risk categories D and X 
there were 76 (5.12 %) and 2 (0.13 %) pDDIs, respectively. The 
software also classified drug interactions based on the severity of the 
interaction as major, moderate, minor, and not classified. Based on this 
classification, the main interactions were in the moderate group-598, 
while major DDIs were noted in 108 patients. 
DISCUSSION 
A total of 199 out of the 239 selected patients (83.3 %) in the study 
were elderly, and 98 % of them received more than 5 drugs 
(polypharmacy) and thus gave us the reason to assign these patients 
as high-risk patients in terms of hazardous pDDIs and their therapy 
needed higher alertness [3, 6, 12]. In addition, 36.1 percent of 
patients had chronic kidney disease and 9.5 percent were with 
chronic renal failure, another contributing factor to the increased 
risk of pDDIs. 
As mentioned above, the most common drug interactions were in the 
risk category C, which required careful monitoring of patients. A total of 
76 out of the 1484 interactions analyzed, were in risk category D (5.12 
%) and their recommendations were, if possible, to consider therapy 
modification, and two were in category X (0.13 %)-avoid combination. 
Based on severity, the software detected 108 major interactions. In table 
2 are presented the most common pDDIs in HF patients associated with 
co-prescribed narrow safety margin medications. Drugs with a narrow 
therapeutic index accounted for nearly 60% (46/76) of the pDDIs in risk 
category D. The examples and the supposed interaction mechanisms are 
discussed in more detail below. 
 





Possible mechanism of 
DDI 
Literature 
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 

















































































*OAT–organic anion transporter; **PD–pharmacodynamics; **PPB-plasma protein binding; ****P-gp–P-glycoprotein 
 
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitors 
(statins) display very complex ADME properties, which include 
uptake transporters (e. g. OATP1B1), biotransformation through 
cytochrome enzymes (e. g. CYP3A4 etc.) and efflux pumps (e. g. 
MDR1). All these processes are vulnerable and predispose to drug 
interactions. Thirteen of the 80 interactions in RRC D (16%) 
involved the use of a statin in combination with a calcium channel 
antagonists from the 1,4-dihydropyridine group. The prescribed 
statin in combination was simvastatin and from the 1,4-
dihydropyridine calcium channel antagonists-amlodipine. The 
recommendations in the prescription information for both 
medicines are that the dose of simvastatin used in the combination 
with amlodipine should not exceed 20 mg [13, 14]. The possible 
mechanism of interaction is not fully known, but it is assumed that it 
is about a competitive relationship with the CYP3A4 enzyme, as both 
preparations are substrates of this enzyme. Another commonly 
prescribed statin, a substrate of CYP3A4 as well, atorvastatin, does 
not indicate an interaction risk with amlodipine. In addition, the two 
drugs are included in a single dosage form for better patient 
adherence and compliance (Caduet® amlodipine/atorvastatin). A 
possible explanation for the different risk for the two substrates of 
CYP3A4 from the statin group is that simvastatin undergoes 
significant first-pass metabolism in the enterocytes of the 
gastrointestinal tract, while atorvastatin undergoes a less 
pronounced one. Interactions of simvastatin with CYP3A4 
modulators are more pronounced compared to atorvastatin, and 
therefore atorvastatin seems to be safer for concomitant use with 
1,4-dihydropyridine calcium channel antagonists [15]. Another 
major in severity and belonging to a risk category D interaction 
involving statins, is the concomitant use with an antigout drug-
colchicine. Only one such interaction was detected. Increased risk of 
myelotoxic effects-myopathy and varying degrees of 
rhabdomyolysis, are observed in patients taking statins with 
colchicine [16]. The possible mechanisms involved in this 
interaction are complex and are most likely to be at both 
pharmacokinetic and pharmacodynamic levels. The 
pharmacokinetic processes where this interaction can occur are the 
cytochrome enzyme-colchicine basically inhibits the activity of 
CYP3A4, but other cytochromes also, as well as the organic anionic 
transporter [17], and thus affects plasma statin levels. 
Pharmacodynamic mechanisms show that both groups of drugs are 
at high risk of developing myopathies [18]. Despite these possible 
PK and PD interactions, co-administration of statins and low-dose 
colchicine is nowadays recommended in patients with the coronary 
disease to stabilize the atherosclerotic plaque, due to inhibition of 
neutrophil function [19]. Another group, in which the combination 
of statins increases the risk of muscular toxicity, is the group of 
fibrates. The severity of the reaction is classified as major, while in 
terms of risk, it is in Category C-monitoring of symptoms of muscle 
damage and when it is suspected or diagnosed, immediate 
discontinuation of both drugs is necessary. Among the fibrates, 
fenofibrate has shown the lowest risk of myopathy and the 
interaction potential with HMG-CoA-reductase inhibitors [20], and it 
is the only one registered and used fibrate in Bulgaria. The exact 
mechanism is not fully known, but it is assumed that mostly 
pharmacodynamic components take part. 
Anticoagulants, and especially the group of vitamin K antagonists, 
pose a high risk of drug interactions and require increased attention. 
Drug interactions of this group include PK and PD mechanisms, such 
as displacement of binding with plasma proteins, induction or 
inhibition of cytochrome P450 isozymes, alterations in vitamin K 
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status or contribution of hemorrhagic or thrombotic risk. Sixty-six 
patients were treated with acenocoumarol in the study. Ten of them 
showed pDDIs, category D with major severity, and were selected 
for discussion. The first case was interaction with allopurinol, a 
xanthin oxidase inhibitor, which is used in the treatment of gout. In 
this interaction, the ability of allopurinol to inhibit the metabolism of 
coumarin anticoagulants is likely to increase the risk of bleeding and 
needs close monitoring for increased prothrombin times (PT) [21]. 
The interaction of acenocoumarol with sulfamethoxazole/ 
trimethoprim (SMZ/TMP) is supposed to be more complicated. The 
result is a further increased risk of bleeding, but the mechanisms 
suggested include displacement from the plasma protein binding 
site, inhibition of metabolism (by inhibiting CYP2C9), but also 
affecting the intestinal flora responsible for vitamin K synthesis. 
Recommendations for using this combination are both dose 
reduction of coumarin anticoagulant and patient education for close 
monitoring of the INR (international normalized ratio) values [22]. 
The third and the fourth detected interactions were with the 
preparation of the fibrate group-fenofibrate and antiarrhythmic 
drug-amiodarone. The putative mechanisms of these interactions 
include inhibition of CYP2C9, the isozyme of P-450 primarily 
responsible for the conversion of (S)-warfarin to its major 
metabolite, (S)-7-hydroxywarfarin. Concomitant use of 
acenocoumarol with fenofibrate or amiodarone may result in a 
twofold increase in INR values; therefore, the recommendations are 
empirically reducing 20% of the dose of coumarin anticoagulant and 
careful monitoring of INR to see if more dose reduction is needed 
[23]. Coumarin anticoagulants show a notable effect in hyperthyroid 
patients compared to hypothyroid ones. The reason for this is the 
more pronounced metabolism of vitamin K-dependent blood 
clotting factors in patients with increased thyroid function. Hence, in 
patients receiving thyreostatics, such as methimazole and 
propylthiouracil, the effects of vitamin K antagonists can be 
compromised [24]. There is a need to monitor the changes in thyroid 
function and a need of dose adjustment of coumarin anticoagulants. 
Among non-vitamin K oral anticoagulants (NOACs), dabigatran was 
the most commonly prescribed to the patients. Dabigatran etexilate 
is a direct thrombin inhibitor and it is indicated for the treatment of 
AF, deep vein thrombosis (DVT) and/or pulmonary embolism (PE) 
[25]. A pharmacokinetic feature of dabigatran is that it is a substrate 
of P-glycoprotein/ABCB1, and interactions with inhibitors, e. g. 
amiodarone, verapamil or carvedilol, of this efflux pump may occur. 
Management of this pDDI depends on the indication and the kidney 
function of the patient. Recommendations are in the treatment or 
prophylaxis of venous thromboembolism (VTE) and CrCL 
(creatinine clearance)<50 ml/min or in the treatment of AF with 
CrCL<30 ml/min to avoid concurrent use of dabigatran etexilate 
with amiodarone, verapamil or carvedilol due to the risk of bleeding 
[25, 26]. Оther agents in the NOAC group are direct inhibitors of 
factor Xa, such as rivaroxaban and apixaban. Like dabigatran, these 
preparations are substrates of P-gp and, in addition, of CYP3A4 as 
well. One major drug interaction (RRC D) is detected, a combination 
of rivaroxaban with verapamil–moderate CYP3A4 inhibitor and P-gp 
inhibitor. Although in a large retrospective study, concomitant use of 
rivaroxaban with moderate inhibitors of CYP3A4 and P-gp did not 
significantly increase the risk of major bleeding [26], 
recommendations are for cautious use of these drugs, especially in 
patients with creatinine clearance<80 ml/min [27]. 
Clopidogrel, an oral inhibitor of the platelet P2Y12 receptor for 
adenosine 5’-diphosphate (ADP), is often a part of dual antiplatelet 
therapy (DAPT) along with aspirin. The pharmacokinetic feature of 
clopidogrel that makes it susceptible to drug interactions is the 
biotransformation that it undergoes in the liver to form its active 
metabolite. The formation of an active metabolite is comprised of 
two steps and the major cytochrome, which takes part is CYP2C19 
[28]. Proton pump inhibitors (PPIs), e. g. Omeprazole, esomeprazole, 
lansoprazole, pantoprazole and rabeprazole, are commonly 
combined with DAPT for reducing the incidence of serious 
gastrointestinal hemorrhages [29]. Proton pump inhibitors may 
inhibit the activity of CYP2C19 and the formation of the active 
metabolite of clopidogrel. The highest potential for clinically 
significant interaction was observed for omeprazole and 
esomeprazole. It was lower for lansoprazole and lowest for 
pantoprazole and rabeprazole [30]. 
Drug interactions in risk category D, not related to the above-
mentioned groups, accounting for 40% of them, are presented in 
table 3. 
 
Table 3: pDDIs in HF patients associated with drugs, other than statins, anticoagulants and antithrombotic drugs 
pDDI Severity/Risk category Frequency Possible mechanism of DDI 
Beta-blockers+Alfa2-agonists or I1-agonists Moderate/D 18 (23.7%) PD* 
Torasemide+NSAIDs Major/D 3 (0.07%) PD 
Azithromycin+Amiodarone, Sotalol Major/D 2 (0.13%) Increase of QTc 
Allopurinol+Lisinopril Major/D 2 (0.13%) Increase hypersensitivity 
Torasemide+Methotrexate Major/D 1 (0.9%) OAT** 
Methotrexate+Etoricoxib Major/D 1 (0.9%) OAT 
Amlodipine+Clarithromycin Moderate/D 1 (0.9%) CYP3A4 
Sitagliptine+Sulfonylureas Major/D 1 (0.9%) PD 
*PD–pharmacodynamics; **OAT–organic anion transporter  
 
The most frequent reaction was the interaction of beta-blockers 
with alpha2-agonists or imidazoline I1-receptor agonists. Although 
the reaction belongs to risk category D, the severity is considered 
moderate. The recommendations include heart rate monitoring, 
because of the increased risk of sinus node dysfunction or the onset 
of an AV block. 
Two interactions fell in risk category X (avoid combination) and the 
both were the combination of cefuroxime with lansoprazole. This 
drug interaction has not been evaluated in any clinical study. 
Cefuroxime axetil salt is stable in lower pH, therefore drugs, which 
increase pH of the stomach, will reduce the solubility and decrease 
the bioavailability [31]. The recommendation in the prescription 
information of cefuroxime axetil is to avoid concurrent use with 
proton pump inhibitors. 
Limitation of the study 
In the present study, a single program for the analysis of potential 
drug interactions was used. The reason for this is the detailed 
information provided by the software, the precise mechanisms of 
interaction (where known), the available information, the 
recommendations and the many available references. The other 
available softwares have also been tested, but in the end, we have 
been working with this one. Another limitation of the study was that 
no data was provided for these patients after their discharge from 
the hospital. However, a significant number of patients are included 
in the study in order for the conclusions to be made. 
CONCLUSION 
HF patients are at high risk of pDDIs. The review of patients' 
prescriptions for potential drug interactions should be done by 
using the appropriate software and/or a clinical pharmacist 
experienced in drug interactions. Moreover, we need to monitor the 
patient response and associated adverse effects, in order to discover 
the undescribed or unexplained interaction reactions. This is the 
only possible way to find and prevent significant side effects and 
eventually to improve the patient safety. 
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